Ikponmwosa Jude Ogieuhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ikponmwosa Jude Ogieuhi has a total of 371 co-authors. Here are the top co-authors by number of shared publications:
Victor Oluwatomiwa Ajekiigbe
Ladoke Akintola University of Technology, Ogbomosho, Nigeria
30 shared publications- Chidera Stanley Anthony
University of Calabar, Calabar, Nigeria
27 shared publications Adetola Emmanuel Babalola
Kornberg School of Dentistry, Temple University, Philadelphia, USA
13 shared publicationsAdewunmi Akingbola
University of Cambridge, Cambridge, UK
12 shared publicationsChinonyelum Emmanuel Agbo
Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria
12 shared publicationsGbolahan Olatunji
Johns Hopkins University, Baltimore, USA
11 shared publications
Latest Publications
- 28 July 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (4) , 528-544
Blood plasma adipomyokine levels and proteinaseinhibitory activity in sarcopenic obesity
BACKGROUND: The search for diagnostic markers reflecting muscle function, protein catabolism, and adipose tissue metabolism in sarcopenia is an important medical problem. AIM: To assess the levels of asprosin (adipokine), meteorinlike protein (myokine), and proteinaseinhibitory activity in blood plasma, and their relationship with metabolic parameters and sarcopenia criteria in sarcopenic obesity and during the presarcopenic phase. METHODS: The study included 50 participants (38 women, 12 men) aged 45–85 years. Of these, 11 had sarcopenia (reduced strength and mass), 16 had presarcopenia (reduced strength), and 23 served as controls (no strength or mass loss). We measured asprosin, meteorinlike protein, elastase and trypsinlike proteinase activity, and alpha1proteinase inhibitor in plasma. RESULTS: In sarcopenic obesity, asprosin correlated positively with fat mass (rs = 0.73, p = 0.012) and negatively with muscle strength (rs = −0.81, p = 0.023). Asprosin was higher in sarcopenia without obesity than in sarcopenic obesity: 9.200 (8.500; 9.300) vs 7.100 (6.000; 7.900) ng/mL (p = 0.045). Meteorinlike protein exceeded the upper reference limit (179–1990 pg/mL) in 50% of controls (up to 2191–2871 pg/mL) and 25% of presarcopenic participants (up to 2275–4647 pg/mL). In sarcopenic obesity, meteorinlike protein correlated negatively with Cpeptide (rs = −0.74, p = 0.005) and HOMAIR (rs = −0.79, p = 0.011). In controls, meteorinlike protein was lower in hypertensive participants, while both meteorinlike protein and asprosin were lower in type 2 diabetes. Proteinaseinhibitor imbalance in presarcopenia included increased trypsinlike activity (1.5fold) and decreased elastaselike activity (23%). Trypsinlike activity correlated with SARCF score (rs = 0.69, p = 0.02) and reduced performance. Higher alpha1proteinase inhibitor was associated with lower strength (rs = −0.62, p = 0.03) and muscle mass (rs = −0.63, p = 0.04) in controls, and with slower gait speed (rs = −0.9, p = 0.02) in presarcopenic obese participants. CONCLUSION: Adipomyokine dysfunction and plasma proteinaseinhibitor imbalance, combined with metabolic disturbances, may play a role in the development of sarcopenic obesity.
- 28 July 2026
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 107 (4) , 528-544
Blood plasma adipomyokine levels and proteinaseinhibitory activity in sarcopenic obesity
BACKGROUND: The search for diagnostic markers reflecting muscle function, protein catabolism, and adipose tissue metabolism in sarcopenia is an important medical problem. AIM: To assess the levels of asprosin (adipokine), meteorinlike protein (myokine), and proteinaseinhibitory activity in blood plasma, and their relationship with metabolic parameters and sarcopenia criteria in sarcopenic obesity and during the presarcopenic phase. METHODS: The study included 50 participants (38 women, 12 men) aged 45–85 years. Of these, 11 had sarcopenia (reduced strength and mass), 16 had presarcopenia (reduced strength), and 23 served as controls (no strength or mass loss). We measured asprosin, meteorinlike protein, elastase and trypsinlike proteinase activity, and alpha1proteinase inhibitor in plasma. RESULTS: In sarcopenic obesity, asprosin correlated positively with fat mass (rs = 0.73, p = 0.012) and negatively with muscle strength (rs = −0.81, p = 0.023). Asprosin was higher in sarcopenia without obesity than in sarcopenic obesity: 9.200 (8.500; 9.300) vs 7.100 (6.000; 7.900) ng/mL (p = 0.045). Meteorinlike protein exceeded the upper reference limit (179–1990 pg/mL) in 50% of controls (up to 2191–2871 pg/mL) and 25% of presarcopenic participants (up to 2275–4647 pg/mL). In sarcopenic obesity, meteorinlike protein correlated negatively with Cpeptide (rs = −0.74, p = 0.005) and HOMAIR (rs = −0.79, p = 0.011). In controls, meteorinlike protein was lower in hypertensive participants, while both meteorinlike protein and asprosin were lower in type 2 diabetes. Proteinaseinhibitor imbalance in presarcopenia included increased trypsinlike activity (1.5fold) and decreased elastaselike activity (23%). Trypsinlike activity correlated with SARCF score (rs = 0.69, p = 0.02) and reduced performance. Higher alpha1proteinase inhibitor was associated with lower strength (rs = −0.62, p = 0.03) and muscle mass (rs = −0.63, p = 0.04) in controls, and with slower gait speed (rs = −0.9, p = 0.02) in presarcopenic obese participants. CONCLUSION: Adipomyokine dysfunction and plasma proteinaseinhibitor imbalance, combined with metabolic disturbances, may play a role in the development of sarcopenic obesity.
- 14 July 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 304
Achalasia Management in Africa: A Scoping Review of Treatment Outcomes, Challenges, and Strategies for Enhancing Care
- 14 July 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 304
Achalasia Management in Africa: A Scoping Review of Treatment Outcomes, Challenges, and Strategies for Enhancing Care
- Open Access
- 14 July 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (7) , 377
Wearable Devices and Machine Learning in Cardiovascular Monitoring: Current Evidence and Future Directions for Precision Medicine
Cardiovascular disease remains the leading global health challenge, claiming approximately 19.8 million lives annually. The convergence of wearable technology and artificial intelligence represents a transformative shift in cardiovascular healthcare, enabling continuous real-time monitoring beyond conventional clinical settings. This narrative review synthesises current evidence on integrating consumer-grade and medical-grade wearable devices with AI algorithms for continuous cardiovascular monitoring applications, with particular attention to real-world translational applicability and global health equity. This review examined the technological landscape of wearable cardiovascular monitoring devices, including smartwatches with photoplethysmography and electrocardiogram capabilities, continuous cardiac monitoring patches, and emerging biosensor technologies. Also, the review explored AI methodologies, particularly machine learning and deep learning architectures, employed in processing complex physiological data streams from these devices. Clinical applications demonstrate impressive capabilities: arrhythmia detection with sensitivity rates exceeding 98%, continuous blood pressure monitoring through cuffless technologies, heart failure decompensation prediction, and cardiovascular risk stratification. However, substantial challenges persist, including data quality assurance, algorithm interpretability, regulatory compliance, and seamless clinical workflow integration. Privacy concerns, health disparities in algorithm performance, and the need for robust validation across diverse populations remain critical considerations. AI-enhanced wearable systems hold considerable potential for shifting cardiovascular care from reactive treatment paradigms towards predictive, preventive, and precision medicine approaches. Future directions include edge computing architectures, federated learning approaches, personalised AI models, enhanced interoperability with electronic health records, and expansion to resource-limited settings, ultimately improving patient outcomes whilst reducing healthcare costs.
- 14 July 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (7) , 377
Open AccessWearable Devices and Machine Learning in Cardiovascular Monitoring: Current Evidence and Future Directions for Precision Medicine
Cardiovascular disease remains the leading global health challenge, claiming approximately 19.8 million lives annually. The convergence of wearable technology and artificial intelligence represents a transformative shift in cardiovascular healthcare, enabling continuous real-time monitoring beyond conventional clinical settings. This narrative review synthesises current evidence on integrating consumer-grade and medical-grade wearable devices with AI algorithms for continuous cardiovascular monitoring applications, with particular attention to real-world translational applicability and global health equity. This review examined the technological landscape of wearable cardiovascular monitoring devices, including smartwatches with photoplethysmography and electrocardiogram capabilities, continuous cardiac monitoring patches, and emerging biosensor technologies. Also, the review explored AI methodologies, particularly machine learning and deep learning architectures, employed in processing complex physiological data streams from these devices. Clinical applications demonstrate impressive capabilities: arrhythmia detection with sensitivity rates exceeding 98%, continuous blood pressure monitoring through cuffless technologies, heart failure decompensation prediction, and cardiovascular risk stratification. However, substantial challenges persist, including data quality assurance, algorithm interpretability, regulatory compliance, and seamless clinical workflow integration. Privacy concerns, health disparities in algorithm performance, and the need for robust validation across diverse populations remain critical considerations. AI-enhanced wearable systems hold considerable potential for shifting cardiovascular care from reactive treatment paradigms towards predictive, preventive, and precision medicine approaches. Future directions include edge computing architectures, federated learning approaches, personalised AI models, enhanced interoperability with electronic health records, and expansion to resource-limited settings, ultimately improving patient outcomes whilst reducing healthcare costs.
- Open Access
- 6 July 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 80
Primary congenital glaucoma in African children: a scoping review of treatment outcomes and barriers to care
Background: Primary congenital glaucoma (PCG) is an uncommon but serious cause of childhood visual loss. In African settings, children often present late, with advanced disease. However, the evidence on treatment outcomes and barriers to care has not yet been comprehensively mapped. Methods: We searched PubMed, Scopus, Google Scholar, EMBASE, Web of Science, African Journals Online, and African Index Medicus for English-language studies published between January 2011 and January 2026. Eligible studies reported treatment approaches, outcomes, complications, or barriers to care for children with PCG in Africa. Findings were synthesized narratively. Results: Ten studies involving 746 eyes from Tanzania, Ghana, Nigeria, Senegal, Ethiopia, Egypt, and Tunisia were included. Most were retrospective single-center studies. Mean age at presentation, where reported, ranged from 4.8 ± 3.6 months in Nigeria to 2.7 years in Ethiopia, while mean age at diagnosis was reported as 4.4 months in Ghana and 19 months in Tanzania. Mean age at surgery was reported as 5.2 ± 2.9 months in the Nile Delta cohort in Egypt, 5.9 months in Tunisia, and 8.1 ± 5.9 months in Nigeria. Bilateral disease, corneal edema, enlarged corneal diameters, and raised intraocular pressure were commonly reported. Surgery was the main reported treatment approach. Combined trabeculotomy-trabeculectomy was commonly used in more advanced cases, while angle procedures were used when corneal clarity allowed. Postoperative intraocular pressure reduction was reported, and short- to medium-term surgical success ranged from 72.7% to 91.6%. Longer follow-up showed a decline from 91.6% at 1 year to 54.3% at 10 years in Tunisia. Visual outcomes were less consistent, and poor follow-up, delayed referral, limited surgical infrastructure, and cost were frequently reported barriers. Conclusion: PCG in African children remains marked by delayed diagnosis, advanced disease at presentation, and barriers to care. Improving outcomes will likely require earlier recognition, stronger referral and follow-up systems, wider access to pediatric glaucoma expertise, and more robust multicenter prospective research.
- 6 July 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 80
Open AccessPrimary congenital glaucoma in African children: a scoping review of treatment outcomes and barriers to care
Background: Primary congenital glaucoma (PCG) is an uncommon but serious cause of childhood visual loss. In African settings, children often present late, with advanced disease. However, the evidence on treatment outcomes and barriers to care has not yet been comprehensively mapped. Methods: We searched PubMed, Scopus, Google Scholar, EMBASE, Web of Science, African Journals Online, and African Index Medicus for English-language studies published between January 2011 and January 2026. Eligible studies reported treatment approaches, outcomes, complications, or barriers to care for children with PCG in Africa. Findings were synthesized narratively. Results: Ten studies involving 746 eyes from Tanzania, Ghana, Nigeria, Senegal, Ethiopia, Egypt, and Tunisia were included. Most were retrospective single-center studies. Mean age at presentation, where reported, ranged from 4.8 ± 3.6 months in Nigeria to 2.7 years in Ethiopia, while mean age at diagnosis was reported as 4.4 months in Ghana and 19 months in Tanzania. Mean age at surgery was reported as 5.2 ± 2.9 months in the Nile Delta cohort in Egypt, 5.9 months in Tunisia, and 8.1 ± 5.9 months in Nigeria. Bilateral disease, corneal edema, enlarged corneal diameters, and raised intraocular pressure were commonly reported. Surgery was the main reported treatment approach. Combined trabeculotomy-trabeculectomy was commonly used in more advanced cases, while angle procedures were used when corneal clarity allowed. Postoperative intraocular pressure reduction was reported, and short- to medium-term surgical success ranged from 72.7% to 91.6%. Longer follow-up showed a decline from 91.6% at 1 year to 54.3% at 10 years in Tunisia. Visual outcomes were less consistent, and poor follow-up, delayed referral, limited surgical infrastructure, and cost were frequently reported barriers. Conclusion: PCG in African children remains marked by delayed diagnosis, advanced disease at presentation, and barriers to care. Improving outcomes will likely require earlier recognition, stronger referral and follow-up systems, wider access to pediatric glaucoma expertise, and more robust multicenter prospective research.
- 3 July 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 278
The burden of keratoconjunctivitis sicca in Nigeria: a scoping review of prevalence and risk factors
Background Keratoconjunctivitis sicca, commonly known as Dry Eye Disease (DED), is a multifactorial disorder of the ocular surface characterised by tear film instability, ocular discomfort, and visual disturbance. The burden of DED has increased globally and is associated with several environmental, demographic, and ocular risk factors. Despite its growing public health importance, a comprehensive, nationally representative estimate of the prevalence and risk factors of DED in Nigeria is lacking, with existing evidence characterised by significant heterogeneity in study design, diagnostic criteria, and regional coverage. This scoping review summarises the available evidence on DED and its public health significance in Nigeria, maps knowledge gaps, and identifies areas for future research. Methodology A comprehensive search was conducted across PubMed, Google Scholar, ScienceDirect, African Journals Online (AJOL), and grey literature for studies published within the past 18 years. Eligible studies investigated keratoconjunctivitis sicca or dry eye disease (DED) among human populations in Nigeria. Data were synthesised thematically in a narrative form. Eligible studies investigated keratoconjunctivitis sicca or dry eye disease (DED) among human populations in Nigeria. Data were synthesised thematically in a narrative form. Results Thirteen studies (n = 4,217) conducted in Nigeria that met the inclusion criteria were included. Various study designs, including cross-sectional, longitudinal, and case–control, were represented. Across studies, the prevalence rates among adults were high, with more than a quarter of the population affected, the highest being in Oyo State. The highest clinical prevalence was observed in studies focusing on specific co-morbidities, such as 58.2% in non-diabetics in a Lagos hospital and 76% among diabetic patients in Kaduna State. Regarding demographic factors, age, gender, and educational level were identified as risk factors for DED. Conclusion Keratoconjunctivitis sicca represents a significant but often under-recognised ocular health burden in Nigeria, particularly affecting older adults, females, and individuals with systemic and environmental risk factors. DED may also contribute to visual impairment both as a primary condition and as a comorbidity. Effective prevention and management necessitate strengthening awareness, improving screening in clinical and community settings, and expanding research across underserved regions.
- 3 July 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 278
The burden of keratoconjunctivitis sicca in Nigeria: a scoping review of prevalence and risk factors
Background Keratoconjunctivitis sicca, commonly known as Dry Eye Disease (DED), is a multifactorial disorder of the ocular surface characterised by tear film instability, ocular discomfort, and visual disturbance. The burden of DED has increased globally and is associated with several environmental, demographic, and ocular risk factors. Despite its growing public health importance, a comprehensive, nationally representative estimate of the prevalence and risk factors of DED in Nigeria is lacking, with existing evidence characterised by significant heterogeneity in study design, diagnostic criteria, and regional coverage. This scoping review summarises the available evidence on DED and its public health significance in Nigeria, maps knowledge gaps, and identifies areas for future research. Methodology A comprehensive search was conducted across PubMed, Google Scholar, ScienceDirect, African Journals Online (AJOL), and grey literature for studies published within the past 18 years. Eligible studies investigated keratoconjunctivitis sicca or dry eye disease (DED) among human populations in Nigeria. Data were synthesised thematically in a narrative form. Eligible studies investigated keratoconjunctivitis sicca or dry eye disease (DED) among human populations in Nigeria. Data were synthesised thematically in a narrative form. Results Thirteen studies (n = 4,217) conducted in Nigeria that met the inclusion criteria were included. Various study designs, including cross-sectional, longitudinal, and case–control, were represented. Across studies, the prevalence rates among adults were high, with more than a quarter of the population affected, the highest being in Oyo State. The highest clinical prevalence was observed in studies focusing on specific co-morbidities, such as 58.2% in non-diabetics in a Lagos hospital and 76% among diabetic patients in Kaduna State. Regarding demographic factors, age, gender, and educational level were identified as risk factors for DED. Conclusion Keratoconjunctivitis sicca represents a significant but often under-recognised ocular health burden in Nigeria, particularly affecting older adults, females, and individuals with systemic and environmental risk factors. DED may also contribute to visual impairment both as a primary condition and as a comorbidity. Effective prevention and management necessitate strengthening awareness, improving screening in clinical and community settings, and expanding research across underserved regions.
- 23 June 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (7)
The burden of cardiovascular disease in prostate cancer: prevalence, pathophysiology, and implications for integrated care
Cardiovascular disease (CVD) and cancer are the two leading health issues in the world, with CVD being the leading cause of death in all age groups and cancer, particularly prostate cancer (PCa), emerging as a significant concern among elderly men. Common risk factors like metabolic disorders, chronic inflammatory diseases, and hormone abnormalities have been theorized to be responsible for the increasing prevalence of these diseases. In this study, we examined the relationship between CVD and PCa, with emphasis on the pathophysiological events that connect them and how their coexistence affects patient outcomes. Common PCa treatments, such as androgen deprivation therapy (ADT) as well as androgen receptor signaling inhibitors (ARSI), have been linked to higher rates of hypertension, myocardial infarction, arrhythmias, and metabolic abnormalities. These cardiovascular side effects complicate the effective management of PCa, resulting in poorer overall results. It is essential to implement new integrated approaches to tackle these comorbid conditions. Recommendations include changes in lifestyle, personalized treatment plans, multidisciplinary collaborative efforts, and routine cardiovascular examinations for patients on PCa treatment. Evidence found that personalized exercise regimens and pharmaceutical treatments like statins and antihypertensives may lower cardiovascular risks and enhance outcomes in patients undergoing PCa treatment. Also, emerging technological interventions like wearable devices and telemedicine, such as smartwatches and mobile ambulatory blood pressure monitors (ABPMs), offer real-time cardiovascular monitoring and improve health outcomes among these patients. This study identifies the substantial gaps in clinical guidelines, notably in cardio-oncology integration, and emphasizes the importance of further research into biomarkers, shared inflammatory pathways, and individualized therapy methods. Hence, addressing these gaps will enable a more comprehensive approach to patient care, improving their quality of life and survival.
- 23 June 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (7)
The burden of cardiovascular disease in prostate cancer: prevalence, pathophysiology, and implications for integrated care
Cardiovascular disease (CVD) and cancer are the two leading health issues in the world, with CVD being the leading cause of death in all age groups and cancer, particularly prostate cancer (PCa), emerging as a significant concern among elderly men. Common risk factors like metabolic disorders, chronic inflammatory diseases, and hormone abnormalities have been theorized to be responsible for the increasing prevalence of these diseases. In this study, we examined the relationship between CVD and PCa, with emphasis on the pathophysiological events that connect them and how their coexistence affects patient outcomes. Common PCa treatments, such as androgen deprivation therapy (ADT) as well as androgen receptor signaling inhibitors (ARSI), have been linked to higher rates of hypertension, myocardial infarction, arrhythmias, and metabolic abnormalities. These cardiovascular side effects complicate the effective management of PCa, resulting in poorer overall results. It is essential to implement new integrated approaches to tackle these comorbid conditions. Recommendations include changes in lifestyle, personalized treatment plans, multidisciplinary collaborative efforts, and routine cardiovascular examinations for patients on PCa treatment. Evidence found that personalized exercise regimens and pharmaceutical treatments like statins and antihypertensives may lower cardiovascular risks and enhance outcomes in patients undergoing PCa treatment. Also, emerging technological interventions like wearable devices and telemedicine, such as smartwatches and mobile ambulatory blood pressure monitors (ABPMs), offer real-time cardiovascular monitoring and improve health outcomes among these patients. This study identifies the substantial gaps in clinical guidelines, notably in cardio-oncology integration, and emphasizes the importance of further research into biomarkers, shared inflammatory pathways, and individualized therapy methods. Hence, addressing these gaps will enable a more comprehensive approach to patient care, improving their quality of life and survival.
- 20 May 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1)
Pediatric hydrocephalus in Nigeria: a scoping review of management, treatment outcomes, and challenges
Pediatric hydrocephalus continues to pose a significant neurosurgical challenge in Nigeria driven by delayed diagnosis, barriers to treatment, and loss to long-term follow-up. Systemic, infrastructural, and socioeconomic limitations in hydrocephalus care persist across sub-Saharan Africa (SSA) despite major advances globally. This scoping review maps the current landscape of pediatric hydrocephalus in Nigeria, with emphasis on management trends, treatment outcomes, and context-specific challenges. We searched PubMed, Scopus, Web of Science, African Journals Online (AJOL), Nigerian Journal Online (NJOL), as well as grey literature, for studies published within the past 15 years. Eligible studies reported causes, management approaches, treatment outcomes, or barriers to care. Data were synthesized thematically in narrative form. Ten hospital-based studies (n = 1,127) conducted at tertiary institutions and spanning multiple geopolitical zones in Nigeria were included. All were cohort studies (eight retrospective and two prospective) and reported a male predominance. Congenital hydrocephalus, most commonly attributed to aqueductal stenosis and Chiari II malformations, was more common in infants and young children (40-90% across studies), while post-infectious causes were more common in older children. Ventriculoperitoneal (VP) shunting was the predominant treatment modality, while endoscopic third ventriculostomy (ETV) was used in a few centers. Shunt infections were the most common complication, with rates ranging from 11% to 28%. Late presentation was reported with presentation ages ranging between 1 and 12 months of age. High out-of-pocket expenses, limited access to advanced imaging, lack of trained neurosurgeons, and sociocultural barriers to timely care were among the challenges encountered. Pediatric hydrocephalus in Nigeria is characterized by delayed presentation, limited treatment options, and geographical disparities in care. Although ETV is gaining popularity as a treatment modality, VP shunting remains the standard of care. To improve outcomes, neurosurgical services should be decentralized, community-level awareness enhanced, insurance coverage expanded, and national guidelines for hydrocephalus management established.
- 20 May 2026
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1)
Pediatric hydrocephalus in Nigeria: a scoping review of management, treatment outcomes, and challenges
Pediatric hydrocephalus continues to pose a significant neurosurgical challenge in Nigeria driven by delayed diagnosis, barriers to treatment, and loss to long-term follow-up. Systemic, infrastructural, and socioeconomic limitations in hydrocephalus care persist across sub-Saharan Africa (SSA) despite major advances globally. This scoping review maps the current landscape of pediatric hydrocephalus in Nigeria, with emphasis on management trends, treatment outcomes, and context-specific challenges. We searched PubMed, Scopus, Web of Science, African Journals Online (AJOL), Nigerian Journal Online (NJOL), as well as grey literature, for studies published within the past 15 years. Eligible studies reported causes, management approaches, treatment outcomes, or barriers to care. Data were synthesized thematically in narrative form. Ten hospital-based studies (n = 1,127) conducted at tertiary institutions and spanning multiple geopolitical zones in Nigeria were included. All were cohort studies (eight retrospective and two prospective) and reported a male predominance. Congenital hydrocephalus, most commonly attributed to aqueductal stenosis and Chiari II malformations, was more common in infants and young children (40-90% across studies), while post-infectious causes were more common in older children. Ventriculoperitoneal (VP) shunting was the predominant treatment modality, while endoscopic third ventriculostomy (ETV) was used in a few centers. Shunt infections were the most common complication, with rates ranging from 11% to 28%. Late presentation was reported with presentation ages ranging between 1 and 12 months of age. High out-of-pocket expenses, limited access to advanced imaging, lack of trained neurosurgeons, and sociocultural barriers to timely care were among the challenges encountered. Pediatric hydrocephalus in Nigeria is characterized by delayed presentation, limited treatment options, and geographical disparities in care. Although ETV is gaining popularity as a treatment modality, VP shunting remains the standard of care. To improve outcomes, neurosurgical services should be decentralized, community-level awareness enhanced, insurance coverage expanded, and national guidelines for hydrocephalus management established.
- 5 May 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (5) , e70681
Trends in Cardiovascular Mortality Associated With Systemic Connective Tissue Disorders in the United States: A 22‐Year Population‐Based National Analysis (1999–2020)
Aim: To examine national trends and disparities in cardiovascular mortality associated with systemic connective tissue disorders (CTDs) in the United States from 1999 to 2020. Methods: We analyzed mortality data from the CDC WONDER database. Deaths were included where CTD (ICD‐10: M05, M06, M30–M35) was the underlying cause and cardiovascular disease was a contributing cause. Age‐adjusted mortality rates (AAMRs) per 1 000 000 were calculated using the 2000 US Standard Population. Joinpoint regression identified annual and average annual percentage changes. Analyses were stratified by sex, race/ethnicity, census region, and urbanization. Disease subgroup and state‐level analyses were performed. Results: Between 1999 and 2020, 47 752 cardiovascular deaths occurred among individuals with systemic CTDs. The national AAMR declined from 14.4 to 8.2 per 1 000 000 (AAPC: −2.68%, 95% CI: −2.89 to −2.47, p < 0.001). Females had consistently higher mortality than males (average AAMR: 13.5 vs. 5.9 per 1 000 000; p < 0.001). Non‐Hispanic Black individuals had the highest rates (average AAMR: 14.9 per 1 000 000), with widening disparities after 2008. Rural areas had higher mortality than urban areas (average AAMR: 11.4 vs. 9.9 per 1 000 000; p = 0.01). Subgroup analyses revealed heterogeneous trends across CTD subtypes, with SLE showing the slowest improvement (AAPC: −1.87%) and dermatomyositis the steepest decline (AAPC: −4.98%). State‐level AAMRs ranged 2.2‐fold, from 6.3 (District of Columbia) to 13.6 (Montana) per 1 000 000. Conclusions: Cardiovascular mortality associated with systemic CTDs has declined significantly over two decades; however, persistent racial disparities, urban–rural differences, heterogeneous disease‐specific trends, and substantial geographic variation underscore the need for targeted, equitable interventions in this high‐risk population.
- 5 May 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (5) , e70681
Trends in Cardiovascular Mortality Associated With Systemic Connective Tissue Disorders in the United States: A 22‐Year Population‐Based National Analysis (1999–2020)
Aim: To examine national trends and disparities in cardiovascular mortality associated with systemic connective tissue disorders (CTDs) in the United States from 1999 to 2020. Methods: We analyzed mortality data from the CDC WONDER database. Deaths were included where CTD (ICD‐10: M05, M06, M30–M35) was the underlying cause and cardiovascular disease was a contributing cause. Age‐adjusted mortality rates (AAMRs) per 1 000 000 were calculated using the 2000 US Standard Population. Joinpoint regression identified annual and average annual percentage changes. Analyses were stratified by sex, race/ethnicity, census region, and urbanization. Disease subgroup and state‐level analyses were performed. Results: Between 1999 and 2020, 47 752 cardiovascular deaths occurred among individuals with systemic CTDs. The national AAMR declined from 14.4 to 8.2 per 1 000 000 (AAPC: −2.68%, 95% CI: −2.89 to −2.47, p < 0.001). Females had consistently higher mortality than males (average AAMR: 13.5 vs. 5.9 per 1 000 000; p < 0.001). Non‐Hispanic Black individuals had the highest rates (average AAMR: 14.9 per 1 000 000), with widening disparities after 2008. Rural areas had higher mortality than urban areas (average AAMR: 11.4 vs. 9.9 per 1 000 000; p = 0.01). Subgroup analyses revealed heterogeneous trends across CTD subtypes, with SLE showing the slowest improvement (AAPC: −1.87%) and dermatomyositis the steepest decline (AAPC: −4.98%). State‐level AAMRs ranged 2.2‐fold, from 6.3 (District of Columbia) to 13.6 (Montana) per 1 000 000. Conclusions: Cardiovascular mortality associated with systemic CTDs has declined significantly over two decades; however, persistent racial disparities, urban–rural differences, heterogeneous disease‐specific trends, and substantial geographic variation underscore the need for targeted, equitable interventions in this high‐risk population.
- 25 April 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 146
Aldosterone Synthase Inhibitors: a Review of Lorundrostat and Baxdrostat in Treatment-Resistant Hypertension
- 25 April 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 146
Aldosterone Synthase Inhibitors: a Review of Lorundrostat and Baxdrostat in Treatment-Resistant Hypertension
- Open Access
- 16 April 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Pulmonary artery denervation in pulmonary hypertension: mechanism, efficacy, and future directions
- 16 April 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessPulmonary artery denervation in pulmonary hypertension: mechanism, efficacy, and future directions